Business Wire

NY-BOTIFY

13.12.2022 10:01:55 CET | Business Wire | Press release

Share
Botify Expands Executive Leadership and Advisory Bench in Response to Widespread Industry Push to Leverage the Power of Organic Search

Botify, the leading enterprise software company for performance-driven organic search, is closing out 2022 by appointing a series of global executive hires and company advisors. The decision comes in response to continued industry and company growth, illustrating the company’s commitment to driving innovation, delivering excellence across all areas of the business and supporting customers with every opportunity to leverage organic search as a high-impact performance marketing channel.

“I’m thrilled to welcome Brian Marin, Phil Young, Vincent Gonnot, A.J. Ghergich, and Steve Sadove to Botify as we expand how we help global brands improve how they are found in organic search,” said Botify CEO, Adrien Menard. “Each of these leaders will be extremely instrumental in supporting our continued growth and new announcements in the coming months. As we embrace widespread recognition of the impact organic search has on company performance, and define Botify’s next chapter to meet growing demand, I’m confident that together, we will do great things.”

Former Smartly.io executive Brian Marin joined in August as Senior Vice President of Global Services. In this newly created role, Marin will launch a consulting service practice and expand professional services to meet continued customer demand. A seasoned digital marketer, Marin brings decades of SaaS experience and a proven track record building and leading services functions for companies in hyper-growth mode.

Joining Marin’s growing team, Botify welcomed A.J. Ghergich as Vice President of Consulting Services to lead the rollout of Botify’s new consulting service offering. Ghergich brings more than 15 years of organic search and digital marketing experience consulting for Fortune 500 global brands.

Phil Young, Vice President of Sales of Northern Europe, joined Botify in July, focusing on leading sales teams across Northern Europe including the UK, Denmark, Finland, Sweden, and the Netherlands. Young will be working closely with the marketing and product teams to drive growth and ensure the highest success level for his teams. Young brings more than 25 years’ experience driving sales results and joins Botify from Sitecore, the leading provider of end-to-end digital experience software, where he was Area Vice President of Northern EMEA.

Focusing on European expansion, Vincent Gonnot also joined Botify as Vice President of Sales Central/South EMEA in December. Similar to Young, Gonnot will be working alongside the marketing and product teams to ensure optimal regional growth for the company. Gonnot has more than 20 years of international sales and management experience across large companies and startups.

Additionally, Steve Sadove, Principal at Stephen Sadove and Associates, has joined Botify as an advisor, helping to provide high-level counsel to inform the company’s continued growth trajectory. Throughout his career serving as CEO of several retail and consumer brands, Sadove has mastered a deep understanding of how leveraging the right technologies can transform the entire landscape for a business. He will be instrumental in helping Botify achieve amplified success as an essential solution across global organizations.

About Botify
Botify is a global, enterprise software company focused on enabling the most ambitious brands to leverage organic search as a high-impact, performance marketing channel. Powered by AI and a proprietary unified data model, Botify’s platform ensures web and mobile sites are optimized for search, the foundation of being found by consumers in today’s dynamic digital environment. As the leader in organic search innovation, Botify is trusted by more than 500 of the world’s most visible brands, including Expedia, L'Oréal, Crate & Barrel, and The New York Times, all of whom have succeeded in leveraging organic search for exponential, long-term results and revenue growth.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005241/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye